| Period | Period Low | Period High | Performance | |
|---|---|---|---|---|
| 1-Month | 17.09 +10.32% on 03/04/25 |
Period Open: 19.07
| 21.55 -12.48% on 03/12/25 | -0.21 (-1.10%) since 02/28/25 |
| 3-Month | 17.09 +10.32% on 03/04/25 |
Period Open: 30.70
| 31.17 -39.49% on 01/02/25 | -11.84 (-38.57%) since 12/27/24 |
| 52-Week | 11.70 +61.20% on 04/23/24 |
Period Open: 15.63
| 34.13 -44.74% on 12/18/24 | +3.23 (+20.67%) since 03/28/24 |
Explore the exciting world of NovoCure (NASDAQ: NVCR) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential...
NVCR earnings call for the period ending December 31, 2024.
NovoCure reported a solid jump in revenue, but earnings fell short due to rising costs and adoption challenges.
Cancer-targeting biotech NovoCure (NASDAQ: NVCR) had some highly positive news from the laboratory to deliver earlier this week, and investors couldn't grab hold of the stock fast enough. This momentum...
The life science industry recently gave folks diagnosed with pancreatic cancer the best news this group has received in a very long time. A new treatment option that significantly raises their chances...
The trial met its primary endpoint, showing a statistically significant improvement in median overall survival.
NVCR earnings call for the period ending September 30, 2024.
The S&P 500 Index ($SPX ) (SPY ) today is down by -0.08%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up by +0.31%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down by -0.48%. Stocks today are mixed....
USA News Group – Treatments for various forms of breast cancer continue to evolve, with several new breakthroughs being labeled as landmark in nature and giving hope to families dealing with a fateful...
Today Foundation Medicine, Inc. , a pioneer in molecular profiling for cancer, and Relay Therapeutics (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process...
CAMBRIDGE, Mass., July 28, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the...
End-of-phase 1 meeting with the U.S. Food and Drug Administration (FDA) resulted in alignment on the design of a single arm trial for pan-FGFR (FGFRi)...
End-of-phase 1 meeting with the U.S. Food and Drug Administration (FDA) resulted in alignment on the design of a single arm trial for pan-FGFR (FGFRi)...
CAMBRIDGE, Mass., June 16, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the...
CAMBRIDGE, Mass., May 26, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to participate in two fireside chats this month...
CAMBRIDGE, Mass., May 03, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to participate in a fireside chat at the Bank of...
Announced RLY-4008 interim clinical data that suggest it is the first investigational therapy that selectively binds to FGFR2 and avoids off-isoform...
CAMBRIDGE, Mass., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the...
USA News Group – Treatments for various forms of breast cancer continue to evolve, with several new breakthroughs being labeled as landmark in nature and giving hope to families dealing with a fateful...
Today Foundation Medicine, Inc. , a pioneer in molecular profiling for cancer, and Relay Therapeutics (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process...
CAMBRIDGE, Mass., July 28, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the...
End-of-phase 1 meeting with the U.S. Food and Drug Administration (FDA) resulted in alignment on the design of a single arm trial for pan-FGFR (FGFRi)...
End-of-phase 1 meeting with the U.S. Food and Drug Administration (FDA) resulted in alignment on the design of a single arm trial for pan-FGFR (FGFRi)...
CAMBRIDGE, Mass., June 16, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the...
CAMBRIDGE, Mass., May 26, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to participate in two fireside chats this month...
CAMBRIDGE, Mass., May 03, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to participate in a fireside chat at the Bank of...
Announced RLY-4008 interim clinical data that suggest it is the first investigational therapy that selectively binds to FGFR2 and avoids off-isoform...
CAMBRIDGE, Mass., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the...
| Symbol | %Holdings | 3M %Chg |
|---|---|---|
| NVCR | -38.57% | |
| Novocure Ltd Ord Sh | ||
| XHE | 1.58% | -8.51% |
| S&P Healthcare Equipment SPDR | ||
| PTH | 1.57% | -3.95% |
| DWA Healthcare Momentum Invesco ETF | ||
| HTEC | 1.14% | -5.73% |
| Robo Global Healthcare Technology Innovation ETF | ||
| ESGV | 1% | -8.48% |
| ESG U.S. Stock Vanguard ETF | ||
| ITEQ | 0.93% | -4.64% |
| Bluestar Israel Technology ETF | ||
| 3rd Resistance Point | 19.58 |
| 2nd Resistance Point | 19.26 |
| 1st Resistance Point | 19.06 |
| Last Price | 18.86 |
| 1st Support Level | 18.53 |
| 2nd Support Level | 18.21 |
| 3rd Support Level | 18.01 |
| 52-Week High | 34.13 |
| Fibonacci 61.8% | 25.56 |
| Fibonacci 50% | 22.92 |
| Fibonacci 38.2% | 20.27 |
| Last Price | 18.86 |
| 52-Week Low | 11.70 |
